PTGS2 and prostate cancer: It has been reported that COX-2 is overexpressed in endocrine-related primary prostate cancer with metastatic potential and may predict survival [70], while in human breast cancers, COX-2 overexpression is linked to VEGF overexpression and, therefore, tumor angiogenesis [83].